Therefore, key enzymes involved in this pathway (including stearoyl-CoA dehydrogenase [Scd], acetyl-CoA carboxylase [Acc], fatty acid synthase [Fasn], diacylglycerol acyltransferase 2 [Dgat2], and fibroblast growth factor 21 [Fgf21] and Fgf19) for generating liver FAs/TGs have been shown to serve as potential therapeutic targets to prevent NASH progression. The gene discussed is DGAT2; the disease is metabolic dysfunction-associated steatohepatitis.